P1-1 Heterogeneous impact of germline pathogenic variants on lymphoma risk

Yoshiaki Usui
（RIKEN）

P1-2 Primate-specific gene X is a novel prognostic factor in malignant pancreatic cancer

Shoichiro Tange
（Med. Genome Sci., Inst. Frontier Med., Sappor Med. Univ.）

P1-3 Molecular profiling of cancer-related gene alterations in Japanese patients withmultiple myeloma

Yasushi Sasaki
（Biology Division, Department of Liberal Arts and Sciences, Center for Medical Education, Sapporo Medical University）

P1-4 Association of mosaic chromosomal alterations with the development of various types of cancer and body mass index

Keiko Hikino
（RIKEN Center for Integrative Medical Sciences）

P1-5 Characterization of OASEP1 as a biomarker and therapeutic target for oral cancer

Atsushi Takano
（Center for Antibody and Vaccine Therapy, Institute of Medical Science, The University of Tokyo）

P1-6 Substrate charge regulates stemness of cancer and pluripotent stem cells via metabolic control of pluripotency factors

Masamichi Imajo
（Institute for Chemical Reaction Design and Discovery WPI-ICReDD, Hokkaido University）

P1-7 Therapeutic potential of cancer vaccine based on MHC class I cryptic peptides derived from non-coding regions

Serina Tokita
（Department of Pathology, Sapporo Medical University）

P1-8 Identification and functional analysis of HLA class II neoantigens in HLA class II negative colorectal cancer tissues

Satoru Matsumoto
（Department of Pathology, Sapporo Medical University School of Medicine）

P1-9 A lncRNA associated with chronic gastritis and gastric cancer inhibits apoptosis through stress granule formation

Hiroshi Kitajima
（Dept. of Molecular Biology, Sapporo Medical Univ.）

P1-10 Helicobacter pylori CagA causes transient BRCAness to induce genome instability in gastric epithelial cells

Naoko Kamiya
（Hokkaido University）

P1-11 Intratumoral heterogeneity in colorectal cancer -Increasing malignancy of cancer cells by Mfs in tumor budding area-

Rintaro Ohe
（Department of Pathology, Yamagata University Faculty of Medicine）

P2-1 Differences of the molecular mechanisims in dedifferentiation potential of breast cancer cells using hydrogels

Jun Suzuka
（NEXT-Ganken Prog., JFCR）

P2-2 Analysis of novel long non-coding RNA in head and neck cancer.

Takeshi Niinuma
（Sapporo Medical University of Medicine）

P2-3 GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer

Reo Maruyama
（Project for Cancer Epigenomics, Cancer Institute, JFCR）

P2-4 Reduced stromal expressioCXCL12 is associated with the aggressiveness of tongue oral squamous cell carcinoma

Akira Yorozu
（Dept. Otolaryngoly-head and Neck Surgery., Sapporo Med. Univ. Sch. Med.）

P2-5 Analysis of characteristics of synovial sarcoma stem cells induced by synthetic polymer hydrogels

Yuki Terashima
（Sch. of Med. 6th Grade, Hokkaido Univ., Sapporo, Japan）

P2-6 Molecular characterization of HJURP as a new cancer biomarker and therapeutic target for oral cancer

Bayarbat Tsevegjav
（Department of Medical Oncology and Cancer Center, Shiga University of Medical Science ）

P2-7 Tumor-infiltrating CD8+ T cells recognize a heterogeneously expressed neoantigen in clear cell renal cell carcinoma

Masahiro Matsuki
（Hakodate Goryoukaku Hospital）

P2-8 Identification of new targets for pancreatic cancer stem cells using hydroge l and development of therapeutic methods

Lei Wang
（Institute for Chemical Reaction Design and Discovery Hokkaido University）

P2-9 Stromal AEBP1 promotes development of head and neck squamous cell carcinoma

Shohei Sekiguchi
（Department of Oral Surgery., Sapporo Medical University School of Medicine）

P2-10 Genetic analysis of postmortem tissue samples for patient with castration-resistant prostate cancer: A case study.

Ko Okabe
（Department of Urology, Sapporo Medical University School of Medicine）

P2-11 Comprehensive association analysis between clustered microRNA and cancer: a machine learning study with large-scale data

Masanori Nojima
（The Institute of Medical Science, The University of Tokyo）

P2-12 Novel drug formulation for potentiation of therapeutic response using the lymphatic drug delivery system

Radhika Mishra
（Laboratory of Biomedical Engineering for Cancer, Graduate School of Biomedical Engineering, Tohoku University）

P2-13 Targeting lymph node metastasis through lymphatic drug delivery system by administration of docetaxel

Ariunbuyan Sukhbaatar
（Laboratory of Biomedical Engineering for Cancer, Graduate School of Biomedical Engineering, Tohoku University）

P2-14 Identification of URST7 as a prognostic biomarker and therapeutic target for breast cancer

Regina Mbugua
（Dep. Med. Oncol. & Cancer Ctr., Shiga Univ. Med. Sci. Otsu, Shiga, Japan）